Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Lung Neoplasms 3Esophageal Squamous Cell Carcinoma 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Carcinoma, Hepatocellular 2Advanced Solid Tumors 2Advanced Endometrial Cancer 2Advanced Breast Cancer 2Thrombosis 1Thrombophilia 1Solid Tumors 1Small Cell Lung Carcinoma 1Resectable Esophageal Squamous Cell Carcinoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Non-Muscle Invasive Bladder Neoplasms 1Neuroma 1Neoplasms 1

Interventions

Oxaliplatin 4Capecitabine 3Radiotherapy 2Docetaxel 2Androgen Antagonists 2tislelizumab 1pembrolizumab 1luprolide acetate gel depot 1lenvatinib 1enzalutamide 1cemiplimab 1Surgical Procedures, Operative 1Radiotherapy, Image-Guided 1Poly(ADP-ribose) Polymerase Inhibitors 1PF06821497 1Negative-Pressure Wound Therapy 1Leuprolide 1Leucovorin 1Injections 1Fluorouracil 1Drug Therapy 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Adenocarcinoma × Injections × Clear all
NCT06942767 2025-04-27

Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2 Not yet recruiting
100 enrolled
Tumor-Agnostic

Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡